Los puntos clave no están disponibles para este artículo en este momento.
Key Points Selective myeloma cell killing and enhanced effector function of a novel anti-BCMA antibody conjugated with MMAF via noncleavable linker. Specific multiple myeloma antigen for monoclonal antibody-based immunotherapy.
Tai et al. (Wed,) studied this question.